<DOC>
	<DOC>NCT01042977</DOC>
	<brief_summary>This study is carried out to assess whether dapagliflozin improves glycemic control, decreases fasting plasma glucose levels, body weight and blood pressure when added to patient's existing medications and how it compares with their usual treatment without added dapagliflozin. Safety data will be collected and analysed to confirm that treatment with dapagliflozin is safe and well tolerated in patients who have diabetes and cardiovascular disease</brief_summary>
	<brief_title>Efficacy and Safety in Patients With Type 2 Diabetes Mellitus and Cardiovascular Disease</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Cardiovascular Diseases</mesh_term>
	<criteria>Type 2 diabetes mellitus. Cardiovascular disease Uninterrupted antidiabetic treatment for at least 8 weeks before enrolment Patients with type 1 diabetes or diabetes insipidus Patients with 3 or more oral antihyperglycaemic drugs with or without insulin and/or poorly controlled diabetes Any clinically significant illness, which would compromise the patient's safety and their participation in the study</criteria>
	<gender>All</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>dapagliflozin</keyword>
	<keyword>diabetes</keyword>
	<keyword>cardiovascular disease</keyword>
</DOC>